Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer
Conditions:  Locally Advanced Rectal Carcinoma;  Rectal Adenocarcinoma;  Stage II Rectal Cancer AJCC v8;  Stage IIA Rectal Cancer AJCC v8;  Stage IIB Rectal Cancer AJCC v8;  Stage IIC Rectal Cancer AJCC v8;  Stage III Rectal Cancer AJCC v8;  Stage IIIA Rectal Can cer AJCC v8;  Stage IIIB Rectal Cancer AJCC v8;  Stage IIIC Rectal Cancer AJCC v8 Interventions:  Drug: Capecitabine;  Radiation: Radiation Therapy;  Drug: Ropidoxuridine Sponsor:  National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Radiation Therapy | Rectal Cancers | Research | Xeloda